INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
businesswire.com
news
2022-06-03 00:00:00

June 02, 2022 08:00 PM Eastern Daylight Time BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Spero Therapeutics, Inc. ('Spero' or the 'Company') (NASDAQ: SPRO) investors concerning the Company's possible violations of federal securities laws.



On October 28, 2021, Spero announced that it had submitted a New Drug Application ('NDA') to the U.S. Food and Drug Administration ('FDA') for its urinary tract infection treatments, tebipenem HBr.

On March 31, 2022, Spero released its fourth quarter and full year 2021 financial results, disclosing that the FDA had notified the Company that it had 'identified deficiencies' in the NDA 'that preclude discussion of labeling and post-marketing requirements/commitments.
